双成药业(002693) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥77,156,090.24, an increase of 1.42% compared to the same period last year, and a total revenue of ¥250,820,096.29 for the year-to-date, representing a 32.06% increase year-on-year [4]. - The net profit attributable to shareholders for Q3 2021 was a loss of ¥10,030,477.37, a decrease of 16.35% year-on-year, with a year-to-date loss of ¥4,033,651.26, which is an improvement of 84.29% compared to the previous year [4]. - The basic earnings per share for Q3 2021 was -¥0.02, unchanged from the previous year, while the year-to-date basic earnings per share improved by 83.33% to -¥0.01 [4]. - Total operating revenue for the third quarter of 2021 reached ¥250,820,096.29, an increase of 32% compared to ¥189,934,854.06 in the same period of 2020 [22]. - Net loss for the third quarter was ¥18,380,105.56, an improvement from a net loss of ¥40,206,899.50 in the previous year [23]. - The company reported a gross profit margin of approximately -14.4% for the third quarter, compared to -21.2% in the same quarter of the previous year [22]. - The company’s basic earnings per share improved to -0.01 from -0.06 year-on-year [24]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥6,694,673.44, reflecting a significant increase of 125.22% compared to the same period last year [4]. - The net cash flow from operating activities for Q3 2021 was ¥6,694,673.44, a significant improvement compared to the negative cash flow of ¥26,544,315.80 in the same period last year, indicating a turnaround in operational performance [26]. - Cash inflow from operating activities was ¥287,613,654.57, compared to ¥223,753,222.34 in the same period last year, marking a 29% increase [25]. - Total cash outflow from operating activities amounted to ¥280,918,981.13, up from ¥250,297,538.14 in Q3 2020, reflecting increased operational expenditures [26]. - The net cash flow from investing activities was ¥33,932,543.21, recovering from a negative cash flow of ¥54,071,973.46 in the previous year, suggesting improved investment management [26]. - Cash inflow from investment activities totaled ¥237,823,157.12, down from ¥508,841,081.23 in Q3 2020, indicating a decrease in cash recovery from investments [26]. - Cash outflow for capital expenditures was ¥203,890,613.91, significantly lower than ¥562,913,054.69 in the same quarter last year, showing reduced investment in fixed assets [26]. - The net cash flow from financing activities was negative at -¥35,904,922.61, compared to a positive cash flow of ¥44,176,763.51 in Q3 2020, indicating challenges in financing [26]. - The total cash and cash equivalents at the end of the period increased to ¥10,474,398.10 from ¥6,222,465.34, reflecting a positive cash position [26]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥866,027,099.88, a decrease of 4.59% from the end of the previous year [4]. - The total liabilities decreased to ¥100,522,340.03 from ¥129,408,743.59 year-over-year [19]. - The total liabilities decreased to ¥279,765,207.40 from ¥309,365,841.74, a reduction of approximately 10% [20]. - The total equity attributable to shareholders of the parent company increased slightly to ¥495,145,029.64 from ¥492,925,341.02 [20]. - The company’s long-term borrowings remain stable at ¥167,000,000.00 [19]. - The company experienced a 93.13% decrease in short-term borrowings compared to the beginning of the year, due to repayment of bank loans [7]. Operational Highlights - The company reported a 32.06% increase in operating revenue year-on-year, driven by increased product sales and processing business volume [9]. - The company's operating costs increased by 48.36% year-on-year, primarily due to higher product sales volume [9]. - The company reported a 1,190.12% increase in asset disposal gains year-on-year, mainly from the completion of the rights transfer of a product [9]. - The company received FDA approval for its product, Exenatide Injection, for market entry in the U.S. [16]. - The company plans to increase its European subsidiary's registered capital by €50,000, raising it from €10,000 to €60,000 [15]. - The company’s development expenditure increased to ¥87,986,446.94 from ¥69,915,599.62 year-over-year [19]. - Research and development expenses decreased to ¥6,868,488.95 from ¥8,303,280.00, reflecting a reduction of 17% year-on-year [23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,919 [13]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 33.86% of shares, totaling 139,516,546 shares [13]. Tax and Employee Costs - The company reported a total payment to employees of ¥40,151,021.90, which is an increase from ¥31,438,133.77 in the previous year, indicating higher labor costs [26]. - Tax payments amounted to ¥25,457,777.14, slightly up from ¥24,093,613.41 in Q3 2020, reflecting stable tax obligations [26]. Compliance and Standards - The company did not require adjustments to the opening balance sheet for the new leasing standards implemented in 2021, indicating compliance with the updated accounting regulations [27].